Zomarist is commonly used to help manage Type 2 Diabetes Mellitus in adults when symptoms related to systemic imbalance are not adequately controlled by single-agent therapy. The medication is relevant when patients are unable to achieve or maintain target blood glucose levels using the maximally tolerated dose of metformin alone. Its therapeutic use encompasses situations of monotherapy failure, the simplification of regimens for patients already stable on the separate components, and use as part of a triple combination therapy with agents like a sulphonylurea or insulin.

This combination may assist with blood glucose management and stabilization, which helps patients cope more steadily with symptom fluctuations. The fixed-dose format also contributes to improved day-to-day comfort by easing the complexity of the patient's medication schedule.

“This therapeutic approach is primarily relevant for patients needing a consistent daily dosage regimen to maintain functional stability.”

Quick Fact: Support for HbA1c Stability

Quick Fact: Relief for Poor Long-Term Glucose Control

Zomarist is applied in addressing the long-term markers of blood sugar control, such as elevated Glycosylated Haemoglobin (HbA1c). Use of Zomarist, by helping stabilize HbA1c, is considered relevant for supporting the body during symptomatic periods and may contribute to easing the overall symptom load.

Regulatory References

1. European Medicines Agency (EMA) overview

This medication, a combination of vildagliptin and metformin, is approved for use in adults with Type 2 Diabetes Mellitus. It should not be used in children or adolescents under 18 years of age, as safety and efficacy have not been established.

Contraindicated Populations (Must Not Use)

Zomarist is contraindicated in patients with the following conditions, as stated in regulatory documents:

• Hypersensitivity to the active substances or any excipients.
• Severe renal failure or renal dysfunction, defined as a Glomerular Filtration Rate (GFR) less than 30 mL/min.
• Any type of acute metabolic acidosis (e.g., lactic acidosis, diabetic ketoacidosis) or diabetic pre-coma.
• Hepatic impairment, including those with pre-treatment elevated liver enzymes (ALT or AST ge 3 times the upper limit of normal).
• Acute conditions that could suddenly alter renal function, such as severe infection, shock, dehydration, or when receiving an intravascular iodinated contrast agent.
• Acute or chronic disease that may cause tissue hypoxia (e.g., cardiac or respiratory failure, recent myocardial infarction, or shock).
• Acute alcohol intoxication or alcoholism.
• Breast-feeding (lactation).

Restricted or Not Recommended Use

• It is not recommended for use in patients with Type 1 Diabetes Mellitus or in those with NYHA functional class III-IV heart failure.
• Temporary discontinuation is required before elective surgery involving general anesthesia and before or during administration of iodinated contrast agents.

Interactions with other medicines and products

Zomarist is a fixed-dose combination containing vildagliptin and metformin hydrochloride. The interaction profile reflects the documented effects of both active components, as confirmed by regulatory agencies.

Key Interaction Constraints

Interacting Product Category	Potential Effect and Constraint
Iodinated Contrast Agents	Intravascular administration may cause temporary kidney impairment, leading to metformin accumulation and risk of lactic acidosis. Treatment must be temporarily discontinued before and after the procedure.
Medicines Affecting Kidney Function	Products like certain diuretics, antihypertensives, and NSAIDs may affect kidney function or inhibit renal transport, potentially increasing metformin exposure. Use requires careful consideration.
Sulfonylureas and Insulin	Co-administration may result in an increased risk of hypoglycemia (low blood sugar), which may require monitoring.
ACE Inhibitors	Combination with vildagliptin has been associated with a slightly higher incidence of angioedema (swelling).

Procedural and Timing Requirements

Due to the metformin component, Zomarist must be temporarily discontinued at the time of, or prior to, any test involving the intravascular administration of iodinated contrast agents. Treatment should not be resumed until at least 48 hours afterward, only after renal function has been re-evaluated and found to be normal. Similarly, the medicine should be discontinued 48 hours before elective surgery with general anesthesia and typically resumed no earlier than 48 hours after the procedure.

How Zomarist Works

Zomarist, a combination drug, elicits complementary physiological effects across two distinct mechanistic domains to modify systemic pathway activity.

---

Modulating Incretin Hormone Signaling

This domain involves vildagliptin, which selectively inhibits the Dipeptidyl Peptidase-4 (DPP-4) enzyme. Blocking DPP-4 prevents the rapid breakdown of naturally occurring incretin hormones, specifically GLP-1 and GIP. This action prolongs the activity of these mediators, thereby modulating the concentration of active incretin hormones. The resulting cascade potentiates glucose-dependent secretion of insulin from pancreatic beta-cells and suppresses the release of glucagon from pancreatic alpha-cells.

---

Regulating Hepatic Glucose Output

The second mechanistic domain is driven by metformin, a biguanide that modulates key pathways associated with energy metabolism. Metformin works primarily by decreasing the liver's production of glucose via suppression of hepatic gluconeogenesis. Secondary actions include reducing intestinal glucose absorption and promoting increased peripheral glucose uptake. This mechanism influences systemic glucose disposition and pathway activity.

How Zomarist is Used

Zomarist, a fixed-dose combination of vildagliptin and metformin, is approved for oral administration only. Its use follows a protocol focused on providing an individualized daily dose, typically divided into two administrations. The medicine is available in several fixed-dose strengths, such as 50 mg/500 mg, 50 mg/850 mg, and 50 mg/1000 mg (Vildagliptin/Metformin hydrochloride).

Standard Administration and Dosing

The standard pattern of use is twice daily (BID), with one tablet taken in the morning and the other in the evening. To help mitigate common gastrointestinal effects, the tablets are instructed to be taken with or immediately after food. The tablet must be swallowed whole.

The maximum recommended daily dose for the vildagliptin component is 100 mg, while the maximum for metformin is 3000 mg in patients with preserved renal function. Dosage titration is determined by the patient’s existing regimen and tolerance, aiming to maintain long-term management of blood glucose levels.

Administration Constraint	Instruction
Timing	Twice daily, with or immediately after food.
Missed Dose	Take as soon as remembered, but do not double dose on the same day.
Paediatric Use	Not recommended for children and adolescents.

Population-Specific Use Rules

Usage requires strict adherence to renal function limits. Dosing is dependent on the patient's Glomerular Filtration Rate (GFR); for example, the vildagliptin component is limited to a maximum of 50 mg daily when GFR is below 60 mL/min. Regular monitoring of kidney function is a required procedural step before initiating and during therapy.

Research evidence / Overview of studies for Zomarist

---

Evidence for Use in Inadequate Glycaemic Control on Metformin Alone

The primary research exploring the combination of Vildagliptin and Metformin was conducted in adults with Type 2 Diabetes Mellitus whose long-term blood sugar levels ( HbA1c) remained elevated despite treatment with Metformin alone. Researchers conducted multiple Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-Analyses to examine the combination in these patients. Research monitored the change in the biomarker Glycosylated Haemoglobin ( HbA1c) and other blood sugar readings, such as Fasting Plasma Glucose, to track patterns related to glucose levels. Studies monitored the HbA1c values of patients receiving the combination in parallel with those who continued Metformin alone.

However, the follow-up durations were limited in many core trials, typically lasting less than one year. Because of this, long-term effects are not fully established, and there is limited information for long-term outcomes, such as major vascular events like heart attack or stroke. Regulatory reviews also noted that findings were sometimes mixed when evaluating HbA1c changes in certain patient subgroups.

---

Research on Zomarist as Part of Triple Combination Therapy

Research has explored the use of the Vildagliptin/Metformin combination as a component in a triple combination therapy for adults whose condition was already being managed with two other agents, such as a sulphonylurea or insulin. These studies used an add-on design in RCTs and monitored the change in the primary biomarker HbA1c when the combination was added. The evidence contributes to understanding the patterns of glucose level changes observed in patients when the combination was introduced.

Comparative evidence is lacking to directly evaluate the combination against every other possible triple-drug regimen. Furthermore, data for combining the Vildagliptin/Metformin combination with a specific class of drugs called a thiazolidinedione are still insufficient, and research has not established the efficacy structure for this particular triple oral therapy.

Common questions about Zomarist (FAQ)

---

Q: Why is Zomarist considered different from other medicines for the same condition?

A: Zomarist is a fixed-dose combination containing two active substances, vildagliptin (a DPP-4 inhibitor) and metformin (a biguanide), which work through different mechanisms to improve blood sugar control. Regulatory documents indicate that the fixed-dose combination structure is clinically recognized for supporting adherence, which is a key differentiator from single-agent medicines.

Q: What is the longest period of time Zomarist is usually taken for?

A: Clinical trials examining the safety of the vildagliptin and metformin combination have explored use for periods of up to two years. As Type 2 Diabetes is a chronic condition, the medicine is generally utilized as a component of a continuous, long-term management plan.

Q: What kind of foods or drinks might cause an interaction with Zomarist?

A: Official product information indicates that alcohol use, particularly acute intoxication, is associated with an increased risk of the rare but serious complication called lactic acidosis. Taking the tablets with or immediately after food is a known recommendation to help mitigate common gastrointestinal side effects.

Q: Does taking Zomarist affect a person’s ability to drive?

A: The official product information reports common side effects such as dizziness and hypoglycemia (low blood sugar), particularly when the medicine is used with certain other diabetes treatments. Due to these potential effects, caution may be warranted regarding driving or operating machinery. Regular monitoring of the patient's condition is required during treatment.

Q: Can Zomarist be used by older adults?

A: Since the metformin component is cleared by the kidneys, and kidney function tends to decrease with age, regulatory guidance requires that older adults have their renal function monitored regularly before and periodically during treatment.

Q: Has Zomarist been approved in countries outside of the United States?

A: Yes, Zomarist is authorized for use in various global regions. It has been approved by the European Medicines Agency (EMA) for use across the European Union, in addition to being referenced in prescribing information from other global authorities.

Q: How long does Zomarist stay in your system after the last dose?

A: Regulatory documents state that due to the risk of accumulation, the medicine must be temporarily discontinued for at least 48 hours before and after certain medical procedures, such as those involving iodinated contrast agents. This required stopping period indicates the time the body takes to clear the medication.

Q: Do the side effects of Zomarist usually go away over time?

A: Official product information states that the very common gastrointestinal side effects, such as nausea, vomiting, and diarrhoea, which are linked to the metformin component, are often more frequent at the start of treatment. This indicates that these specific effects may lessen or resolve with continued use.

Q: Is Zomarist the brand name for the medicine?

A: Yes, Zomarist is a brand name for this fixed-dose combination product. It contains the two active substances vildagliptin and metformin hydrochloride. The medicine may also be available under other brand names, depending on the region.

Q: What is the general long-term outlook for people taking Zomarist?

A: The medicine is generally utilized for the long-term management of Type 2 Diabetes to maintain blood sugar control. While clinical safety studies up to two years did not show new safety concerns, regulatory guidance requires ongoing monitoring for the rare but serious risk of Lactic Acidosis associated with the metformin component.

Q: Is there a generic version of Zomarist available?

A: The medicine containing the same active substances, vildagliptin and metformin, is often available under multiple brand names, such as Eucreas. Depending on the region, it may also be available under a generic name like Vildagliptin/Metformin Hydrochloride.

Q: Does Zomarist cause weight gain or weight loss in most people?

A: Studies and official information indicate that the vildagliptin component, when administered in combination with metformin, is reported as being weight neutral. This indicates that weight neutrality was generally observed in clinical trials examining the combination.

Q: Is tiredness or fatigue a common side effect of Zomarist?

A: Official safety data does not list tiredness or fatigue as a common, isolated side effect. However, asthenia (a lack of energy or physical weakness) is listed as a potential symptom of the rare but serious complication called Lactic Acidosis.

Q: Is Zomarist a controlled substance?

A: The active ingredients in Zomarist are not classified as controlled substances in regulatory schedules. However, it is a prescription-only medicine, meaning it must be obtained with a valid prescription from a healthcare provider.

Q: Is Zomarist known to interact with herbal supplements?

A: Regulatory guidance on the metformin component suggests caution, as herbal remedies and supplements are typically not tested for interactions with the medicine in the same way as prescription drugs. As is standard medical counsel, disclosure of all supplements and remedies to a healthcare provider is generally recommended.

Q: Why do some users report a metallic taste while on Zomarist?

A: Safety data documented in official prescribing information lists metallic taste (known clinically as dysgeusia) as a common side effect. This effect is specifically associated with the metformin component of the medication.

Q: What is the purpose of the black box warning on Zomarist, if it has one?

A: The prescribing information for metformin-containing products generally includes a Boxed Warning (the highest level of safety alert) issued by regulatory bodies. This warning is in place to highlight the rare but serious risk of Lactic Acidosis.

Q: Does Zomarist affect birth control pills?

A: Official documents state that oral contraceptive pills (birth control pills) containing female hormones may affect blood sugar control. Because of this potential effect, simultaneous use requires careful consideration regarding the dose of the metformin component.

Q: Why do official documents describe Zomarist as a first-line treatment?

A: Official product information does not describe Zomarist as a first-line treatment. Instead, it indicates that the medicine is intended for use in patients whose blood sugar is inadequately controlled by the single agent metformin alone. Metformin is commonly considered the first-line treatment.

Q: Does Zomarist interact with common vitamins like Vitamin D?

A: The metformin component is specifically associated with a decrease in Vitamin B12 absorption, which is a listed adverse reaction that may require monitoring. As is standard medical counsel, informing a healthcare provider about all supplements and vitamins taken is generally recommended.

How to Store and Dispose of Zomarist

Official regulatory information defines specific requirements for storing and disposing of this medicine to maintain its quality and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C (degrees Celsius).
Protection	Store in the original package to protect the medicine from moisture.
Child Safety	Keep this medicine strictly out of the sight and reach of children.
Stability	Do not use the medicine after the expiry date (EXP) stated on the carton.

Disposal Instructions

Used or expired medicine must not be disposed of via household waste or by flushing down the wastewater system. To ensure environmentally safe disposal, individuals should consult a pharmacist for instructions on how to properly throw away unused medicines.